Organogenesis Holdings Inc. Third Quarter of Fiscal Year 2026 Earnings Conference Call - ORGANOGENESIS HOLDINGS INC

Explicit Guidance:

• Full-year 2027 total net revenue expected to be $179 million to $200 million, representing a year-over-year decline of 65% to 68%.
• Revenue breakdown assumptions for 2027: Advanced wound care products ($151M–$171M), Surgical and sports medicine products ($26M–$27M), and Grant income ($1.9M).
• Sequential improvement in adjusted EBITDA loss expected for the second half of 2026, with a projected >60% reduction in loss compared to the first half of 2026 (low end) and >80% reduction (high end).
• Target to achieve positive adjusted EBITDA in Q4 2026.
• Annualized expense reduction target of ~$45 million driven by March and June 2026 restructurings ($32M of total) and incremental cost reduction activities.

Business-Segment Outlook:

• Advanced Wound Care: Market expected to bottom out with recovery beginning in Q1 2027; sequential revenue growth observed in Q3 (+6% QoQ) following a 70% YoY decline.
• Product Mix: Expected shift in favor of evidence-based biologic products (AppleGraph, PurePly AM, Affinity, NuShield) as competitors exit; market share gains exceeding 30% vs. Q1.
• Amnuvix (MNuVIC): BLA submission under FDA review; PDUFA date extended to April 24, 2027, contingent on facility remediation completion.
• Manufacturing: Remediation at the Norwood facility expected to be completed by September 30, 2027, to satisfy FDA pre-licensure inspection findings.
• Commercialization: Expectation of double-digit market expansion in the advanced wound care sector once current inventory flush-out concludes.

Market and Competitive Outlook:

• Market share consolidation anticipated, with the landscape expected to stabilize around four to five major competitors possessing quality products and robust clinical evidence.
• Competitive landscape restructuring: Distributor-driven competitors, high-priced amniotic players, and entities with fraudulent practices have been substantially reduced.
• Inventory dynamics: Approximately 20% of Q3 skin substitute sales originated from competitors who have exited the market and are liquidating inventory; this is expected to clear by the end of 2026.
• Pricing vs. Volume: Price stabilization and volume recovery expected to settle out by Q1 2027.
• Regulatory Environment: Anticipation of potential reinstatement of Local Coverage Determinations (LCDs) for skin substitutes, which would further redefine the market toward evidence-backed leaders.

Macro / Industry Outlook:

• Reimbursement & Policy: Uncertainty regarding CMS comments on "discarded product" continues to cause customer confusion, though the trend is shifting back toward efficacy and evidence.
• Clinical Evidence: Management views clinical data and randomized controlled trials (RCTs) as the primary "currency of credibility" and the key driver for future coverage policies.
• Treatment Volume: Long-term demand remains strong as the underlying patient population (non-healing ulcers, osteoarthritis) is unaffected by market consolidation.

Strategic Initiatives:

• Amnuvix (Knee Osteoarthritis): Focus on establishing a new market category for a non-surgical biologic for the 30 million+ Americans with symptomatic knee OA; commercialization is contingent on FDA approval in 2027.
• Clinical Evidence Generation: Continued investment in publishing data (e.g., PREPARE trial for PurePly AM in diabetic foot ulcers) to support future coverage determinations.
• Cost Restructuring: Two rounds of RIFs (reduction in force) and operational efficiencies implemented to reduce the expense profile by $45 million annually.
• Facility Investment: $8 million total remediation cost for Norwood facility ($4M incremental, $4M pulled forward); 25% of remediation spending allocated to 2026, remainder in 2027.
• Financing: Evaluating alternative financing strategies to accelerate Amnuvix commercialization and Smithfields facility enhancements; cash runway sufficient for 12 months from Q3 2026.

Risks and Headwinds to Outlook:

• FDA Compliance: Potential delays in Amnuvix approval if facility remediation at Norwood exceeds the September 30, 2027, timeline.
• Regulatory Uncertainty: Prolonged confusion regarding CMS "discarded product" rules could delay clinician adoption and market recovery.
• Market Volatility: Continued presence of low-cost inventory from exiting competitors could suppress pricing and volume growth into 2027.
• Execution Risk: Achieving positive adjusted EBITDA in Q4 2026 requires hitting the high end of the revenue range while maintaining strict expense discipline.

Management Tone on the Future:

• Confidence: Management expresses strong optimism ("very optimistic," "best positioned," "strong long-term market position") despite current headwinds.
• Strategic Conviction: Confident in the "last man standing" advantage due to the company's diverse FDA classifications and evidence base.
• Guidance Adjustment: Tone reflects a "measured recovery" and acknowledgment that the market bottoming process took longer than anticipated in 2026, with a focus on stabilizing by Q1 2027.

Miscellaneous:

• Financial Health: Cash and equivalents reduced from $94.3M (Dec 2025) to $26.9M (Sep 2026); no outstanding debt.
• Key Milestones: PREPARE trial for PurePly AM achieved primary endpoints; FDA mid-cycle communication regarding clinical data requests received.